Alector is a privately held biotechnology company developing therapies that harness the immune system to cure neurodegenerative diseases and cancer. The company focuses on immuno-neurology and immuno-oncology programs, guided by human genetic studies implicating dysfunctional immune responses in neurodegeneration. Alector has identified a portfolio of drug candidates designed to restore normal immune function in the aging brain and counteract neurodegeneration. It has announced intended indications for three lead neurodegenerative candidates: AL001 for frontotemporal dementia (FTD); AL002, which targets TREM2 implicated in Alzheimer’s disease; and AL003, which targets SIGLEC-3, a prevalent Alzheimer’s risk factor. Alector plans to advance these clinical programs and expand its discovery platform. The company is headquartered in South San Francisco, California, and recently closed a $133 million Series E to fund its clinical and discovery efforts. Alector LLC is a biotech company pioneering the discovery and development of first-in-class immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. The company combines state-of-the-art antibody technology with recent discoveries in neuro-immunology and human genetics to build a platform of therapeutics that harness the immune system to fight dementia and neurodegeneration. Alector’s approach is enabled by a strategic alliance with Adimab for discovery of fully human antibodies and bispecifics. The company aims to efficiently generate and validate antibody drugs that engage genetically validated neuro-immune targets and to advance promising candidates into the clinic. Alector says its strong cash position from recent financings gives it optionality to prioritize and partner across its portfolio while independently progressing drug candidates. The company is actively hiring immunologists and neurobiologists at all levels. Alector has built a platform of next-generation, immuno-modulating antibodies that mobilize the immune system to target multiple disease-causing pathologies in Alzheimer’s and other neurodegenerative diseases. The company focuses on genetically validated targets and antibody drugs, enabled by a strategic alliance with Adimab for discovery of fully human antibodies and bispecifics. Co-founders include Asa Abeliovich, Arnon Rosenthal and Tillman Gerngross. Proceeds from the announced financing will be used to broaden Alector’s drug pipeline and advance its most promising candidates toward clinical trials. The company is actively hiring immunologists and neurobiologists to support its development efforts. The firm presented its approach as applying immuno-oncology–style immune mobilization to neurology. The press release was issued from San Francisco. Alector LLC focuses on discovering and developing novel therapeutics for Alzheimer’s disease, other dementias, and related neurodegenerative disorders. The company combines state-of-the-art antibody technology with recent discoveries in neuroimmunology and human genetics to generate and validate antibody drugs with unique functional properties. Alector has a strategic alliance with Adimab to support discovery and optimization of antibody therapeutics. The founding team includes Arnon Rosenthal, Tillman Gerngross, Asa Abeliovich, and Errik Anderson, who bring expertise in neuroscience, antibody discovery, and biotech management. Alector is developing leads for four major targets and anticipates taking two of these through preclinical development and IND-enabling studies within 24 months. The company recently closed a Series A financing to fund research and development on innovative targets.

Total raised

$195M

Funding rounds

4

Latest round

Series E

Latest activity

Jul 2018